| pubmed-article:10328534 | rdf:type | pubmed:Citation | lld:pubmed |
| pubmed-article:10328534 | lifeskim:mentions | umls-concept:C0007634 | lld:lifeskim |
| pubmed-article:10328534 | lifeskim:mentions | umls-concept:C1519697 | lld:lifeskim |
| pubmed-article:10328534 | pubmed:issue | 1 | lld:pubmed |
| pubmed-article:10328534 | pubmed:dateCreated | 1999-9-2 | lld:pubmed |
| pubmed-article:10328534 | pubmed:abstractText | The tumorigenicity of adenovirus (Ad) 12-transformed mouse cells was evaluated by analyzing the relationship of tumor cell dose to tumor incidence and tumor latency. The tumor producing dose 50% endpoint values used to define these relationships remained stable during 52 weeks of serial passage in tissue culture and were not determined by low frequency events within the cell population. The data from these analyses suggest that the phenotype of Ad12-transformed mouse cells is influenced by two set of traits--those traits that determine the threshold number of cells required for tumor formation and those that extend the cell dose-dependent tumor latency period. Both traits are established independently of cell immortalization, and both can be influenced by the immunological status of tumor-challenged animals. These observations were verified by using mouse cells transformed by Ad5 and SV40. The biological and molecular processes that contribute to these traits remain to be determined. The approach developed by this analysis provides a reliable, quantitative means of evaluating endogenous traits that determine transformed cell tumorigenicity. This method can also be used to test the effects of tumor cell manipulations or changes in host response that could alter expression or detection of these neoplastic cell traits. | lld:pubmed |
| pubmed-article:10328534 | pubmed:language | eng | lld:pubmed |
| pubmed-article:10328534 | pubmed:journal | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:10328534 | pubmed:citationSubset | IM | lld:pubmed |
| pubmed-article:10328534 | pubmed:status | MEDLINE | lld:pubmed |
| pubmed-article:10328534 | pubmed:month | Apr | lld:pubmed |
| pubmed-article:10328534 | pubmed:issn | 0166-0934 | lld:pubmed |
| pubmed-article:10328534 | pubmed:author | pubmed-author:AllingD WDW | lld:pubmed |
| pubmed-article:10328534 | pubmed:author | pubmed-author:LewisA MAMJr | lld:pubmed |
| pubmed-article:10328534 | pubmed:author | pubmed-author:CookJ LJL | lld:pubmed |
| pubmed-article:10328534 | pubmed:author | pubmed-author:SodduSS | lld:pubmed |
| pubmed-article:10328534 | pubmed:author | pubmed-author:BadveV MVM | lld:pubmed |
| pubmed-article:10328534 | pubmed:issnType | Print | lld:pubmed |
| pubmed-article:10328534 | pubmed:volume | 79 | lld:pubmed |
| pubmed-article:10328534 | pubmed:owner | NLM | lld:pubmed |
| pubmed-article:10328534 | pubmed:authorsComplete | Y | lld:pubmed |
| pubmed-article:10328534 | pubmed:pagination | 41-50 | lld:pubmed |
| pubmed-article:10328534 | pubmed:dateRevised | 2007-11-15 | lld:pubmed |
| pubmed-article:10328534 | pubmed:meshHeading | pubmed-meshheading:10328534... | lld:pubmed |
| pubmed-article:10328534 | pubmed:meshHeading | pubmed-meshheading:10328534... | lld:pubmed |
| pubmed-article:10328534 | pubmed:meshHeading | pubmed-meshheading:10328534... | lld:pubmed |
| pubmed-article:10328534 | pubmed:meshHeading | pubmed-meshheading:10328534... | lld:pubmed |
| pubmed-article:10328534 | pubmed:meshHeading | pubmed-meshheading:10328534... | lld:pubmed |
| pubmed-article:10328534 | pubmed:meshHeading | pubmed-meshheading:10328534... | lld:pubmed |
| pubmed-article:10328534 | pubmed:meshHeading | pubmed-meshheading:10328534... | lld:pubmed |
| pubmed-article:10328534 | pubmed:meshHeading | pubmed-meshheading:10328534... | lld:pubmed |
| pubmed-article:10328534 | pubmed:meshHeading | pubmed-meshheading:10328534... | lld:pubmed |
| pubmed-article:10328534 | pubmed:meshHeading | pubmed-meshheading:10328534... | lld:pubmed |
| pubmed-article:10328534 | pubmed:meshHeading | pubmed-meshheading:10328534... | lld:pubmed |
| pubmed-article:10328534 | pubmed:meshHeading | pubmed-meshheading:10328534... | lld:pubmed |
| pubmed-article:10328534 | pubmed:meshHeading | pubmed-meshheading:10328534... | lld:pubmed |
| pubmed-article:10328534 | pubmed:year | 1999 | lld:pubmed |
| pubmed-article:10328534 | pubmed:articleTitle | Evaluating virus-transformed cell tumorigenicity. | lld:pubmed |
| pubmed-article:10328534 | pubmed:affiliation | Viral Pathogenesis Section, Laboratory of Immunopathology National Institutes of Health, Bethesda, MD 20892, USA. | lld:pubmed |
| pubmed-article:10328534 | pubmed:publicationType | Journal Article | lld:pubmed |
| pubmed-article:10328534 | pubmed:publicationType | Research Support, U.S. Gov't, Non-P.H.S. | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:10328534 | lld:pubmed |
